Posted by g_g_g_unit on December 1, 2011, at 21:49:33
In reply to Re: thinking about a benzo » g_g_g_unit, posted by SLS on December 1, 2011, at 21:12:04
I've actually been on both, albeit for rather limited amounts of time. I recall lower doses of Parnate (i.e. 10-20mg) improving my attention, which would be consistent with a stimulant effect, but also being somewhat abrasive and anxiogenic. Higher doses (i.e. 40mg) seemed more anxiolytic, but the insomnia was a pain.
Given that I suffer from comorbid ADHD, I was more interested in revisiting Parnate if Lexapro at a higher dose doesn't work out.
> > Scott, do you think Parnate is a bad treatment choice for anxiety?
>
> Nardil is the MAOI most studied for anxiety disorders, and demonstrates efficacy. I would just note that Parnate was reported by Liebowitz et al. to be as effective as Nardil for treating social phobia. My guess is that the stimulant-like properties of Parnate might complicate things for some people. If you exclude Nardil from consideration, I don't think Parnate would be a bad choice.
>
>
> - Scott
>
>
> --------------------------------------
>
>
> Also:
>
> http://www.ncbi.nlm.nih.gov/pubmed/20036427
>
> Psychiatry Res. 2010 Feb 28;175(3):260-5. Epub 2009 Dec 29.
>
> Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder.
>
> Nardi AE, Lopes FL, Valença AM, Freire RC, Nascimento I, Veras AB, Mezzasalma MA, de-Melo-Neto VL, Soares-Filho GL, King AL, Grivet LO, Rassi A, Versiani M.
>
> Laboratory of Panic & Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro, R Visconde de Piraja, 407/702 Rio de Janeiro, Brazil. antonionardi@terra.com.br
>
> Abstract
>
> Our objective was to explore the dose-response relationship in patients with panic disorder and social anxiety disorder comorbidity (DSM-IV). After 1 week of no-drug washout, 36 such patients were assigned to a double-blind controlled comparison of the effects of 30 mg and 60 mg of tranylcypromine, and were followed up for 12 weeks. The main instrument used to measure the number of panic attacks was the Sheehan Panic and Anticipatory Anxiety Scale. The primary outcome measure for social anxiety disorder symptoms was the mean change from baseline in the Liebowitz Social Anxiety Scale (LSAS). After 12 weeks of treatment, panic attacks were reduced 69.6% from baseline in the 30-mg group (n=19) compared with a 74.8% reduction in the 60-mg group (n=17). Twelve patients (70.6%) of the higher dose group and 14 patients (68.4%) of the lower dose were completely free of panic attacks. There was no difference in efficacy between the tranylcypromine groups in the panic disorder symptoms. The 60-mg dose was more efficacious as measured by the LSAS scores, showing a significant difference in relation to the lower group. Mean change from baseline in LSAS total score (mean+/-SD) for 30-mg group was 17.9+/-14.7 and for the 60-mg group was 35.0+/-14.8. The social anxiety symptom scale showed a two-fold greater change with the 60-mg dose, and the 30-mg dose group could be considered the equivalent of a placebo control group. Tranylcypromine--60 mg daily--was found effective in the treatment of panic disorder and social anxiety disorder comorbidity.
>
> 2008 Elsevier Ltd. All rights reserved.
>
> PMID:
> 20036427
> [PubMed - indexed for MEDLINE]
poster:g_g_g_unit
thread:1003747
URL: http://www.dr-bob.org/babble/20111120/msgs/1004113.html